5.43
-0.04(-0.73%)
Currency In USD
| Previous Close | 5.47 |
| Open | 5.34 |
| Day High | 5.56 |
| Day Low | 5.33 |
| 52-Week High | 6.35 |
| 52-Week Low | 0.4 |
| Volume | 1.86M |
| Average Volume | 2.99M |
| Market Cap | 920.03M |
| PE | 18.1 |
| EPS | 0.3 |
| Moving Average 50 Days | 4.73 |
| Moving Average 200 Days | 3.15 |
| Change | -0.04 |
If you invested $1000 in CytomX Therapeutics, Inc. (CTMX) 10 years ago, it would be worth $412.3 as of February 21, 2026 at a share price of $5.43. Whereas If you bought $1000 worth of CytomX Therapeutics, Inc. (CTMX) shares 5 years ago, it would be worth $639.58 as of February 21, 2026 at a share price of $5.43.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CytomX Therapeutics to Present at Upcoming February Conferences
GlobeNewswire Inc.
Feb 04, 2026 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following conferenc
CytomX Therapeutics Announces Business Update and Company Milestones for 2026
GlobeNewswire Inc.
Jan 08, 2026 1:00 PM GMT
- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan (“Varseta-M”) Phase 1 combination study with bevacizumab in Colorectal Cancer to start in Q1 2026 with initial data expected by 1H
CytomX Therapeutics to Present at Upcoming December Investor Conferences
GlobeNewswire Inc.
Nov 25, 2025 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor